Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) developer of the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, today announced that it will be a featured presenter at the Rodman & Renshaw 16th...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it will begin enrollment this week in a multi-center clinical trial to expand claims for the LuViva® Advanced Cervical Scan to include front-line screening for cervical cancer. The trial will...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced its operating results for the second quarter and six months ended June 30, 2014. Revenue and other income for the second quarter ended June 30, 2014 was approximately $212,000, including...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its second quarter ended June 30,...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has filed an amendment to its premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the LuViva® Advanced Cervical Scan. The filing follows the...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that U.S. Patent and Trademark Office granted a new patent with 22 claims that support the technology behind the LuViva® Advanced Cervical Scan. Patent number 8,781,560 B2 entitled “Method and...
